Transoral robotic surgery (TORS) represents a revolutionary advancement in minimally invasive head and neck cancer treatment. This cutting-edge technology allows surgeons to remove tumors from the throat and base of tongue through the mouth, avoiding external incisions and significantly reducing recovery time. The Advanced Head and Neck, Cranial/Orbital/Maxillofacial Surgery Program at Scripps Prebys Cancer Center offers state-of-the-art TORS for eligible patients with oropharyngeal and laryngeal cancers.
History and Development of TORS
Transoral robotic surgery emerged in the early 2000s as surgeons sought less invasive approaches to head and neck cancer treatment. The da Vinci Surgical System, originally developed for cardiac surgery, was adapted for otolaryngologic applications. FDA approval for TORS in head and neck cancer came in 2009, revolutionizing treatment options. Since then, extensive clinical experience and research have established TORS as a standard treatment modality for select oropharyngeal cancers, particularly HPV-positive tumors. Technological refinements have improved visualization, instrument dexterity, and surgical precision, making TORS increasingly valuable in modern head and neck cancer care.
Indications for TORS
TORS is indicated for select oropharyngeal cancers including tumors of the base of tongue, soft palate, lateral pharyngeal wall, and tonsil. HPV-positive oropharyngeal squamous cell carcinoma represents the primary indication, as these tumors typically respond well to surgical treatment alone or combined with limited adjuvant therapy. TORS is also used for select laryngeal cancers and benign laryngeal pathology. Careful patient selection based on tumor location, size, and patient factors is essential for optimal outcomes. Not all oropharyngeal cancers are suitable for TORS; some require traditional open approaches or non-surgical treatment.
Clinical Studies and Benefits
Extensive clinical research demonstrates TORS effectiveness for oropharyngeal cancer treatment. Studies show oncologic outcomes comparable to traditional open surgery and radiation therapy, with excellent disease control rates. Key advantages include minimally invasive approach with no external incisions, reduced postoperative pain, shorter hospital stay (typically 1-2 days versus 3-5 days for open surgery), faster return to normal diet and function, and reduced long-term swallowing difficulties. Many patients avoid or reduce radiation therapy requirements, eliminating associated side effects including dry mouth, difficulty swallowing, and increased infection risk. Patients report significantly improved quality of life compared to traditional approaches.
Risks and Considerations
While TORS offers substantial benefits, potential risks include bleeding (particularly in the immediate postoperative period), infection, temporary swallowing difficulty, and rarely, airway compromise. Conversion to open surgery may be necessary if adequate visualization cannot be achieved. Temporary throat discomfort and difficulty swallowing are common but typically resolve within 1-2 weeks. Careful patient selection and surgeon experience significantly reduce complication rates. Patients with limited mouth opening, severe trismus, or significant comorbidities may not be ideal candidates. Comprehensive preoperative evaluation ensures appropriate patient selection and realistic outcome expectations.
The TORS Procedure
TORS is performed under general anesthesia with endotracheal intubation. The da Vinci robot is positioned to provide optimal visualization of the oropharynx through the mouth. The surgeon sits at a console with magnified 3D visualization and controls robotic arms with surgical instruments. This setup provides superior visualization compared to traditional transoral approaches and allows precise tumor removal with adequate margins while preserving surrounding structures. The procedure typically lasts 1-3 hours depending on tumor size and complexity.
Recovery and Outcomes
Most TORS patients are discharged within 24-48 hours after surgery. Initial recovery involves throat soreness and mild discomfort managed with pain medication. Patients typically resume soft diet within days and normal diet within 1-2 weeks. Return to normal activities occurs within 2-3 weeks for most patients, compared to 6-8 weeks for open approaches. Long-term swallowing function is typically excellent, with minimal permanent dysphagia. Oncologic outcomes are excellent, with disease-free survival rates comparable to traditional treatments but with substantially improved quality of life.
Expertise and Advanced Technology
Dr. Ravi Garg and our surgical team are experienced in TORS and utilize advanced robotic technology to achieve optimal surgical precision and patient outcomes. Our multidisciplinary approach includes collaboration with medical oncology, radiation oncology, and speech-language pathology to provide comprehensive cancer care. For eligible patients with oropharyngeal cancer, we discuss TORS as a treatment option that may provide superior quality of life outcomes. If you've been diagnosed with oropharyngeal cancer, we invite you to schedule a consultation to determine if TORS is appropriate for your situation.